Expression of p53 Protein and Primary Tumour Volume in Patients with Nasopharyngeal Carcinoma

2004 ◽  
Vol 33 (05) ◽  
pp. 304 ◽  
Author(s):  
Mu-Kuan Chen ◽  
Hong-Shen Lee ◽  
Julia H. Chang ◽  
Cheng-Chuan Chang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
P53 Protein ◽  
Primary Tumour ◽  
Tumour Volume

Primary Tumour Volume Delineation in Nasopharyngeal Carcinoma and Correlation with 1997 AJCC Tumour Stage Classification

2001 ◽  
Vol 30 (04) ◽  
pp. 231 ◽  
Author(s):  
Cheng-Chuan Chang ◽  
Mu-Kuan Chen ◽  
Mu-Tai Liu ◽  
Yung-Sung Wen ◽  
Hwa-Koon Wu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Tumour ◽  
Tumour Volume ◽  
Tumour Stage ◽  
Volume Delineation ◽  
Stage Classification

scholarly journals Prognostic significance of primary tumour volume in nasopharyngeal carcinoma – a single institute study

2019 ◽  
Vol 7 (1) ◽  
pp. 24-29
Author(s):  
Dr. S.D. Shamsundar ◽  
◽  
Dr. Jagannath K.P. ◽  
Dr. Niveditha S. ◽  
Dr. K. Aradhana ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Tumour ◽  
Prognostic Significance ◽  
Tumour Volume

scholarly journals Early intra-treatment diffusion weighted magnetic resonance imaging in patients with recurrent nasopharyngeal carcinoma treated with nivolumab

2020 ◽  
Vol 6 (3) ◽  
pp. 568
Author(s):  
Tiffany Y. So ◽  
Qi-Yong Ai ◽  
Brigette B.Y. Ma ◽  
Ann D. King
Keyword(s):  
Magnetic Resonance Imaging ◽  
Overall Survival ◽  
Magnetic Resonance ◽  
Nasopharyngeal Carcinoma ◽  
Progression Free Survival ◽  
Tumour Volume ◽  
Resonance Imaging ◽  
Free Survival ◽  
Diffusion Weighted ◽  
Weighted Magnetic Resonance Imaging

<p class="abstract">Immune check point inhibitors have demonstrated promising efficacy in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) in phase I and phase II trials. Early identification of treatment response is important in these patients. This report aimed to document the early intratreatment diffusion weighted magnetic resonance imaging (DW-MRI) findings in NPC patients following treatment with the programmed cell death-1 inhibitor, nivolumab. Two consecutive patients with histologically confirmed recurrent undifferentiated NPC treated with nivolumab were prospectively recruited. Nivolumab was administered at a dosage of 3 mg/kg intravenously every 2 weeks. Patients underwent magnetic resonance imaging examinations at baseline, and at 3 and 5 weeks after commencement of treatment. Intratreatment changes in tumour volume and apparent diffusion coefficient (ADC<sub>mean</sub>)were calculated. The endpoints were objective response by response evaluation criteria in solid tumors and survival. In patient 1, an intratreatment ADC increase at 5 weeks corresponded with anatomical tumour volume reduction and a better long-term survival outcome (progression free survival 1.3 years, overall survival 2.9 years). In patient 2, an intratreatment ADC decrease at 5 weeks corresponded to progressive disease and worse outcome (progression free survival 0.0 years, overall survival 0.9 years). Intratreatment ADC changes at 3 weeks were not associated with response outcome. These cases suggest that intratreatment changes in ADC at 5 weeks may potentially predict tumour response in patients treated with nivolumab. Dedicated studies are needed to clarify these findings and fully characterise patterns of treatment related ADC change.</p>

scholarly journals Co-localization of Endogenous and Exogenous p53 Proteins in Nasopharyngeal Carcinoma Cells

1997 ◽  
Vol 45 (7) ◽  
pp. 991-1003 ◽  
Author(s):  
Jenn-Kuo Hwang ◽  
Chin-Tarng Lin
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Cell Line ◽  
Point Mutation ◽  
Transcriptional Activation ◽  
Polyclonal Antibodies ◽  
P53 Protein ◽  
Activation Function ◽  
P53 Mutation ◽  
Polymorphism Analysis ◽  
Mutant P53

Recently, we have established nine nasopharyngeal carcinoma (NPC) cell lines in which only one cell line showed the p53 mutation. For investigation of the p53 mutation in this line, immunostaining using anti-p53 antibody was applied and showed the presence of p53 protein in the cytoplasm but not in the nucleus. Single strand conformation polymorphism analysis of the p53 gene showed one normal and one additional DNA band. Cloning and sequencing of PCR-amplified DNA showed an AGA (arginine) to ACA (threonine) heterozygous point mutation at codon 280. Transfection of the p53 DNA binding sequence and chloramphenicol acetyltransferase assay revealed loss of transcriptional activation function of endogenous p53 protein. Co-localization of the endogenous and the transfected exogenous p53 protein by polyclonal antibodies to anti-p53 protein revealed strong exogenous p53 staining in the transfected nuclei and weak staining of endogenous p53 protein in the cytoplasm. We concluded that (a) a heterozygous point mutation at codon 280 was identified in the NPC-TW 06 cell line; (b) the point mutation may cause the stagnation of mutant p53 protein in the cytoplasm, and loss of its transcriptional activation function; (c) endogenous and exogenous p53 protein can be co-localized at the same time in the transfected cells; and (d) 280 mutant p53 protein in NPC cells does not cause a decrease or increase in sensitivity to chemotherapy.

Two or four hour [18F]FMISO-PET in HNSCC

2011 ◽  
Vol 50 (01) ◽  
pp. 22-27 ◽  
Author(s):  
R. Haase ◽  
A. Koch ◽  
D. Zips ◽  
J. Steinbach ◽  
M. Baumann ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Signal To Noise Ratio ◽  
Primary Tumour ◽  
Prospective Trial ◽  
Tumour Volume ◽  
Test Results ◽  
Non Invasive ◽  
Positron Emission ◽  
Static Images ◽  
The Mean

Summary[18F]Fluoromisonidazole positron emission tomography (FMISO-PET) is a non invasive imaging technique that can assist detecting intra tumour regions of hypoxia. FMISO-PET evinces comparatively low signal-to-noise-ratio (SNR) and may be acquired dynamically or after different uptake times post injection (p. i.). The aim of this study was to identify, if static images acquired two hours (MISO2) or four hours (MISO4) p. i. reveal higher contrast. Patients, methods: As part of a prospective trial, 23 patients with cancers of the head and neck underwent [18F]fluoro deoxyglucose (FDG) PET before and during curative radiochemotherapy. Additionally, FMISO-PET studies 2 h and 4 h p. i. were done before treatment and after a mean dose of 11 Gy, 23 Gy and 57 Gy during RCT. After coregistration, a dedicated software was used to define the gross tumour volume (GTV) by FDG PET for the primary tumour. This volume was overlaid to the FMISO images and hypoxia within the GTV was determined. The contrast between hypoxia determined by MISO2 and by MISO4 was investigated and analysed with the Wilcoxon-matched-pairs test. Results: Mean SUVmax in tumours of all examinations was 2.2 (stdev: 0.4, min: 1.3, max: 3.4) after 2 h and 2.4 (stdev: 0.7, min: 1.1, max: 4.4) after 4 h. In the neck musculature the mean SUVmax was 1.5 at both time points and the mean SUVmean decreased from 1.2 after 2 h to 1.1 after 4 h, respectively. These effects resulted in significantly rising contrast ratios from MISO2 to MISO4. The differently defined contrasts revealed significantly higher values for examinations 4 h p. i. (p < 0.002). Conclusion: Data acquisition of [18F]FMISO should be done 4 h p. i. to gather the optimal contrast, preferably allowing further analysis, e. g. hypoxic sub volume definition for therapy planning.

Multivariate analysis based risk grouping of ewing tumours (ET) with extra-pulmonary metastatic disease (EPMD): Final results from the Euro Ewing 99 study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9562-9562
Author(s):  
R. Ladenstein ◽  
J. Whelan ◽  
O. Oberlin ◽  
C. Weston ◽  
H. Jürgens
Keyword(s):  
Multivariate Analysis ◽  
Primary Tumour ◽  
Local Treatment ◽  
Risk Groups ◽  
Tumour Volume ◽  
Bone Lesions ◽  
Free Survival ◽  
Ewing Tumours ◽  
Single Bone

9562 Background: To identify an effective treatment for patients with EPMD. Methods: 192 patients (pts) were registered. Median age is 15.8 years (yrs) (0.4–49.29). Primary site was extremity in 57 pts and axial/other in 135 pts (40.6% in the pelvis). Tumour volume was ≥ 200 ml in 114pts. Metastatic spread was bone marrow (BM) only in 19 pts, bone only in 93 pts and bone and BM in 79 pts. Six VIDE induction cycles were completed by 168 pts (85%). Local treatment included surgery when possible and/or radiotherapy (Rx) as indicated. Recommended HDT was busulphan (BU) 600 mg/m2 and melphalan (MEL) 140 mg/m2 with PSCR. Median follow up is 4.2 years (range: 1.9–6.6). Results: Partial remission or better was achieved after cycle 6 in 75/116 pts subjected to HDT/SCR (65%). The overall survival at 3 years for all 192 pts is 29% (95% CI=0.04). Significantly favourable univariate factors in the unselected cohort at diagnosis (Dx) were age < 14 yrs (event free survival at 3 yrs (EFS) 37%, p=0.006), BM involvement only (EFS 47%, p=0.024), single bone lesions only (EFS 35%, p=0.009), extremities (EFS 34%, p=0.007) and tumour volume of <200 ml (EFS 47%, p<0.001). For pts receiving BuMel it is noteworthy that 37 pts of <14a and EPMD achieved an EFS of 47% in comparison to older counterparts >14a (EFS 22% (p=0.026). Multivariate analysis identified two major risk factors at Dx: primary tumour volume >200 ml p<0.001 (RR 2.25) and > 5 bone metastases p=0.064 (RR 2.11). In these risk groups the 3 yr EFS was 56% for 35 pts with <200 ml and <5 bone lesions, for 17pts with <200 ml > 5 bone lesions 29%, for 67 pts >200 ml or < 5 bone lesions 19% and extremely dismal for 47 pts with >200 ml and > 5 bone lesions with 7% (p<0.001). Conclusions: Groups with differing prognoses from EPMD have been identified from this prospectively followed cohort. Aggressive treatment with HDT appears effective only for sub groups of patients with EPMD and ET. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document